Printer Friendly

BMI`s Report on Iran Pharmaceuticals and Healthcare Sector.

Business Monitor International is forecasting a 10.2% compound annual growth rate (CAGR) for the Iranian pharmaceutical market, meaning an increase in total value from US$2.25bn in 2008 to US$3.65bn by 2013. BMI believes the main drivers for growth will include a growing population, a rise in domestic drug manufacturing, and the greater burden of disease imposed by respiratory illnesses. Total healthcare spending is expected to rise from US$24.3bn in 2008, to US$50.0bn by 2013, reflecting the increasing demand on medical services. During February 2009, the Iranian government announced the addition of new prescription drugs for multiple sclerosis (MS) and anaemia. The new drugs launched in Iran for the treatment of MS are believed to include an interferon beta-1b. No originator names have been disclosed, however it is possible that the likely candidate is Betaseron manufactured by Bayer Healthcare. Stunningly, a version offingolimod by Novartis has been launched as well as a bio similar version of EMD Serono`s Rebif. The Iranian pharmaceutical firm CinnaGen Biopharma is rumoured to be releasing another interferon beta-1a preparation, despite its first MS drug CinnoVex already available in the country. Iran`s growing population and increased demand for healthcare has led to growing investment in drug manufacturing plants, which will contribute to the rise in exports. BMI predicts the development of local production facilities, which will reduce Iran`s reliance on imported patented products. 2009/05/09

Copyright 2003-2009 Mojnews Agency. All rights reserved

Provided by Syndigate.info an Albawaba.com company

COPYRIGHT 2009 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Moj News Agency (Tehran, Iran)
Date:May 9, 2009
Words:256
Previous Article:BMI`s Report on Iran Pharmaceuticals and Healthcare Sector.
Next Article:Iran, Brazil Held Economic Meeting.
Topics:


Related Articles
Global values Julphar stock at AED3.86 and recommends a 'BUY' on the stock.
Global values Julphar stock at AED3.86 and recommends a ,CyBUY,CO on the stock.
BMI`s Report on Iran Pharmaceuticals and Healthcare.
BMI`s Report on Iran Pharmaceuticals and Healthcare.
Research and Markets: Total Healthcare Spending In Iran Is Expected To Rise from US$24.3bn in 2008, To US$50.0bn By 2013.
BMI`s Report on Iran Pharmaceuticals and Healthcare Sector.
Iran Pharmaceuticals and Healthcare Sector on Rise.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters